Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.


  1. Advanced Patent Search
Publication numberUS20100030048 A1
Publication typeApplication
Application numberUS 12/551,419
Publication date4 Feb 2010
Filing date31 Aug 2009
Priority date4 Mar 1991
Also published asDE69533260D1, DE69533260T2, EP0778897A1, EP0778897A4, EP0778897B1, US5593852, US5965380, US6083710, US6121009, US6162611, US6284478, US6329161, US6514718, US6881551, US7462264, US8588881, US8741590, US20020042090, US20030134347, US20050287620, US20060003398, US20070151869, US20070215491, US20070218097, US20100030044, US20100030046, US20100030047, US20100030049, US20100030050, US20100030051, US20100051479, US20100059370, US20100059371, US20100059372, US20100059373, US20100072063, US20100072064, US20100121165, US20100121166, WO1996006947A1
Publication number12551419, 551419, US 2010/0030048 A1, US 2010/030048 A1, US 20100030048 A1, US 20100030048A1, US 2010030048 A1, US 2010030048A1, US-A1-20100030048, US-A1-2010030048, US2010/0030048A1, US2010/030048A1, US20100030048 A1, US20100030048A1, US2010030048 A1, US2010030048A1
InventorsAdam Heller, Michael V. Pishko
Original AssigneeAbbott Diabetes Care Inc.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Subcutaneous Glucose Electrode
US 20100030048 A1
A small diameter flexible electrode designed for subcutaneous in vivo amperometric monitoring of glucose is described. The electrode is designed to allow “one-point” in vivo calibration, i.e., to have zero output current at zero glucose concentration, even in the presence of other electroreactive species of serum or blood. The electrode is preferably three or four-layered, with the layers serially deposited within a recess upon the tip of a polyamide insulated gold wire. A first glucose concentration-to-current transducing layer is overcoated with an electrically insulating and glucose flux limiting layer (second layer) on which, optionally, an immobilized interference-eliminating horseradish peroxidase based film is deposited (third layer). An outer (fourth) layer is biocompatible.
Previous page
Next page
1. An electrochemical sensor comprising:
one or more non-corroding metal or carbon electrodes;
a sensing layer comprising an enzyme coupled to each electrode; and
a biocompatible layer comprising a biocompatible hydrogel chemically bound to the sensing layer of each electrode.
  • [0001]
    This application is a Continuation of application Ser. No. 11/109,379, filed on Apr. 19, 2005, which is a Continuation application of Ser. No. 10/353,341, filed Jan. 28, 2003, now U.S. Pat. No. 6,881,551, which is a Continuation application of Ser. No. 09/997,808, filed Nov. 29, 2001, now U.S. Pat. No. 6,514,718, which is a Continuation application of Ser. No. 09/668,221, filed Sep. 22, 2000, now U.S. Pat. No. 6,329,161, which is a Continuation of application Ser. No. 09/477,053, filed Jan. 3, 2000, now U.S. Pat. No. 6,162,611, which is a Continuation of application Ser. No. 09/356,102, filed Jul. 16, 1999, now U.S. Pat. No. 6,121,009, which is a Continuation of application Ser. No. 08/767,110, filed Dec. 4, 1996, now U.S. Pat. No. 6,284,478, which is a continuation of application Ser. No. 08/299,526, filed Sep. 1, 1994, now U.S. Pat. No. 5,593,852, which is a continuation-in-part of application Ser. No. 08/161,682, filed Dec. 2, 1993, now U.S. Pat. No. 5,356,786, which is a continuation of application Ser. No. 07/664,054, filed Mar. 4, 1991, now abandoned, which applications are incorporated herein by reference.
  • [0002]
    This work was supported in part by the National Institutes of Health (DK42015). Accordingly, the U.S. government may have rights in this invention.
  • [0003]
    The present invention relates to in vivo enzyme biosensors and more specifically to miniature glucose sensors for subcutaneous measurement of glucose with one-point calibration.
  • [0004]
    In response to the need for frequent or continuous in vivo monitoring of glucose in diabetics, particularly in brittle diabetes, a range of possible in vivo glucose electrodes have been studied. The desired characteristics of these electrodes include safety, clinical accuracy and reliability, feasibility of in vivo recalibration, stability for at least one hospital shift of eight hours, small size, ease of insertion and removal, and a sufficiently fast response to allow timely intervention. The in vivo recalibration should be based upon withdrawal of a single sample of body fluid, e.g., blood, and measuring its glucose concentration. This is termed “one point calibration”.
  • [0005]
    Keys to safety are absence of leachable components, biocompatibility, and limiting of the potentially hazardous foreign matter introduced into the body to an amount that is inconsequential in a worst case failure. The clinical accuracy must be such that even when the readings are least accurate, the clinical decisions based on these be still correct. Feasibility of prompt confirmation of proper functioning of the sensors and of periodic in vivo recalibration is of essence if a physician is to allow the treatment of a patient to depend on the readings of the sensor. This one-point calibration, relying on the signal at zero glucose concentration being zero and measuring the blood glucose concentration at one point in time, along with the signal, is of essence, but has heretofore been elusive. The sensitivity must be sufficiently stable for the frequency of required in vivo recalibration to not be excessive. The sensor must be small enough to be introduced and removed with minimal discomfort to the patient and for minimal tissue damage. It is preferred that the sensor be subcutaneous and that it be inserted and removed by the patient or by staff in a physician's office. Finally, its response time must be fast enough so that corrective measures, when needed, can be timely.
  • [0006]
    In response to some of these needs, needle type and other subcutaneous amperometric sensors were considered. The majority of these utilized platinum-iridium, or platinum black to electrooxidize H2O2 generated by the glucose oxidase (GOX) catalyzed reaction of glucose and oxygen. In these sensors, the GOX was usually in large excess and immobilized, often by crosslinking with albumin and glutaraldehyde. To exclude electrooxidizable interferants, membranes of cellulose acetate and sulfonated polymers including Nafion™ were used. Particular attention was paid to the exclusion of the most common electrooxidizable interferants: ascorbate, urate and acetaminophen. Also to cope with the interferants, two-electrode differential measurements were used, one electrode being sensitive to glucose and electrooxidizable interferants and the other only to interferants. One strategy for overcoming the problem of interferants, applicable also to the present invention, involves their preoxidation. Another strategy involves shifting, through chemical changes, the redox potential of the polymer in the sensing layer to more reducing potentials. When the redox potential of the polymer is in the region between about −0.15 V and +0.15 V versus the standard calomel electrode (SCE), and the electrodes are poised in their in vivo operation between about −0.10 and +0.25 V, the rate of electrooxidation of interferants such as ascorbate, urate, and acetaminophen is very slow relative to that of glucose through its physiological concentration range. Thus, also the currents from electrooxidation of interferants are small relative to those of glucose.
  • [0007]
    To make the electrodes more biocompatible, hydrophilic polyurethanes, poly(vinyl alcohol) and polyHEMA membranes have been used.
  • [0008]
    Several researchers tested GOX-based glucose sensors in vivo and obtained acceptable results in rats, rabbits, dogs, pigs, sheep and humans. These studies validated the subcutaneous tissue as an acceptable glucose sensing site. Good correlation was observed between intravascular and subcutaneous glucose concentrations. They also demonstrated the need for in vivo sensor calibration. Another approach to in vivo glucose monitoring was based on coupling subcutaneous microdialysis with electrochemical detection. To control and adjust the linear response range, electrodes have been made glucose-diffusion limited, usually through glucose transport limiting membranes.
  • [0009]
    Diffusional mediators, through which the O2 partial pressure dependence of the signals is reduced, are leached from sensors. Such leaching introduces an unwanted chemical into the body, and also leads to loss in sensitivity, particularly in small sensors. In microsensors, in which outward diffusion of the mediator is radial, the decline in sensitivity is rapid. This problem has been overcome in “wired” enzyme electrodes, i.e., electrodes made by connecting enzymes to electrodes through crosslinked electron-conducting redox hydrogels (“wires”). Glucose oxidase has been “wired” with polyelectrolyte having electron relaying [Os(bpy)2Cl]+/2+ redox centers in their backbones. Hydrogels were formed upon crosslinking the enzyme and its wire on electrodes. These electrodes had high current densities and operated at a potential of 0.3V vs. SCE. The electrooxidizable interferants are eliminated through peroxidase-catalyzed preoxidation in a second, non-wired, hydrogen peroxide generating layer on the “wired” enzyme electrode.
  • [0010]
    A small (e.g., 0.29 mm), recessed, non-corroding metal (e.g., gold, platinum, palladium) or carbon wire electrode for subcutaneous in vivo glucose monitoring, approaching in its performance all of the above listed requirements, including in vivo one-point calibration, has been produced. The electrode was constructed by depositing active polymer layers into a recess formed by etching away gold from an insulated gold wire.
  • [0011]
    The active polymer layers, including a sensing layer, a glucose flux-limiting layer, a biocompatible layer, and optionally a peroxidase-based interferant eliminating layer, were protected within the recess against mechanical damage. (The peroxidase-based interferant eliminating layer is not required when a lower redox potential polymer is used, as described above.) The recess and its polymer layers also reduced the transport of glucose to the wire electrode contacting sensing layer.
  • [0012]
    By limiting the glucose flux, the desired linear response range, spanning the clinically relevant glucose concentration range was obtained. The inventive biosensors are able to accurately measure, for example, approximately 2-30 mμ glucose and approximately 0.5-10 mμ lactate, in vivo. The sensor has no leachable components, and its four crosslinked polymer layers contain only about 5 μg of immobilized material, and only a few nanograms of polymer-bound osmium. Preoxidation of the interferants in one of the four layers makes possible one-point in vivo calibration of the sensor.
  • [0013]
    FIG. 1 is a schematic drawing of an electrode of the present invention.
  • [0014]
    FIG. 2 is a graphical representation of data generated comparing current density of glucose electrooxidation on electrodes made with PVI5-Os (open triangles) with those made with PVI3-Os (filled triangles).
  • [0015]
    FIG. 3 is a graphical representation of data generated comparing dependency of current generated on the depth of the recess.
  • [0016]
    FIG. 4 is a graphical representation of data generated comparing dependency of the ratio of the current generated and the charge required to electroreduce or oxidize the polymer redox centers in the sensing layer on the thickness of the sensing layer.
  • [0017]
    FIG. 5 is a graphical representation of data generated comparing variation of current generated by electrodes having sensing layers of differing thickness and diffusion limiting layers of different compositions and thickness. Solid circles: 7.5 μm thick sensing layer of PVI5-Os (52%), rGOX (35%), PEGDGE (13%), coated with 4 μm PAL/PAZ (1:1 ratio). Open circles: 5.0 sensing layer. Solid triangles: 12.5 μm sensing layer and 7 μm PAL/PAZ (1:2 ratio). Open triangles: 7.5 μm sensing layer and 4.5 μm PAL/PAZ (1:2 ratio).
  • [0018]
    FIG. 6 is a graphical representation of data generated comparing dependency of current generated on the presence of ascorbate, in the absence and presence of lactate and glucose. The concentrations of ascorbate (A), lactate (L) and glucose (G) are shown. Ascorbate is an electrooxidzable interferant. Upon addition of lactate its electrooxidation current is suppressed while that of glucose is not suppressed.
  • [0019]
    FIG. 7 is a graphical representation of data showing current density and corresponding subcutaneous glucose concentration measured with the subcutaneously implanted electrodes of the present invention in a rat animal model. Large solid circles show blood glucose concentrations measured on withdrawn blood samples using a YSI analyzer.
  • [0020]
    FIG. 8 is a Clarke-type clinical grid analyzing the clinical relevance of the blood glucose measurements of FIG. 7.
  • [0021]
    FIG. 9 is a Clarke-type clinical grid of all possible correlations obtained when each of the 24 glucose analyses of FIG. 7 were used for single point calibration of either implanted electrode.
  • [0022]
    FIG. 10 is a Clarke-type clinical grid testing improvement of the single point calibration through redundant electrodes, the readings of which were within the standard deviation calculated for all differences between simultaneous readings by a pair of implanted electrodes.
  • [0023]
    The present invention includes an insulated, non-corroding conducting metal (e.g., gold, platinum, palladium) or carbon wire-based small (e.g., 290 μm) O.D. subcutaneous glucose sensor, allowing one-point calibration in vivo. As shown in FIG. 1, its construction involves coating a small (e.g., 250 μm) diameter non-corroding metal or carbon wire 2 with an electrically insulating material 4, e.g., a polyimide, and, layering in a recess 6 formed by etching or removing a portion of the metal or carbon, the following active polymeric layers: an immobilized, “wired,” glucose oxidase layer 8; an electrically insulating and glucose diffusion limiting layer 10 formed, for example, by crosslinking a polyallylamine (PAL) with a polyaziridine (PAZ); optionally, an interference eliminating layer 12, e.g., of crosslinked horseradish-peroxidase and lactate oxidase; and a biocompatible film 14 e.g., of poly(ethylene oxide) (PEO) derivatized to allow its photo-crosslinking. The outside diameter a of the wire 2 is preferably about 0.25 mm or less, and the outside diameter b of the insulated wire is preferably about 0.3 mm or less. The recess 6 in the insulated electrode extends from the tip 16 of the electrode which is open to the surrounding environment, to the top 18 of the wire 2 in the insulating sheath, generally for a length c of less than about 0.150 mm, and preferably about 0.125 mm.
  • [0024]
    The electrodes have no leachable components. The total amount of polymers and enzymes is preferably about 5 μg. The glucose response through the physiologically relevant 2-20 mM concentration range is close to linear. The electrodes do not respond to ascorbate, urate or acetaminophenol for at least about 36 hours. Their 10-90% response time is about 90 seconds at 2 mM glucose and about 30 seconds at 20 mM glucose. Their sensitivity, after about 30 minutes equilibration, is stable for about 72 hours at 37° C. in 10 mM glucose, the current deviating from the average by less than .+−.5%. The electrodes have substantially no signal output, e.g., current, charge, or potential, when the concentration of the analyte to be measured is zero.
  • [0025]
    Two electrodes implanted subcutaneously in a rat tracked blood glucose levels, and their absolute, uncorrected current output was proportional to the blood glucose concentration. Analysis of the correlation between the blood glucose levels in the tail vein and the current output of the sensors in the subcutaneous regions of the thorax and between the scapulae of the same rat showed that even when the probed sites and organs differed in the extreme, one point in vivo calibration was valid. The analysis also showed the value of implanting redundant sensors. Had clinical decisions been made based on individual sensor readings, calibrated at one point, 94% would have been clinically correct. By using redundant sensors and accepting only those pairs of readings that were within one standard deviation, the percentage of the clinically correct decisions was increased to 99%.
  • [0026]
    It is understood that one of skill in the art may substitute various components of the biosensor described above with known materials to obtain a modified biosensor using the principles outlined herein. For example, the following substitutions are contemplated:
  • [0027]
    Base electrode: The base electrode of the inventive sensor may be formed of a non-corroding metal or carbon wire, for example vitreous carbon, graphite, platinum, palladium, or gold. Gold is preferred, and is used in the following illustrative examples of the invention.
  • [0028]
    Insulator: The conductive metal or carbon wire is coated with an electrically insulating material, which also forms a wall about the recess which houses the active polymeric components. The insulating material may be, for example, polyurethane, teflon (fluorinated polymers), polyethyleneterephthalate (PET, Dacron) or polyimide. The insulating material is preferably a biocompatible polymer containing less than about 5% water when in equilibrium with physiological body fluids, e.g., subcutaneous tissue.
  • [0029]
    Recess: In general, the recess at the tip of the electrode is approximately 20 to 150 μm in length c, and preferably is approximately 50 to 125 μm.
  • [0030]
    Etching method: The method for etching metal from the tip of the electrode described herein may utilize chloride, bromide or iodide in the bath in lieu of cyanide as described. Bromide is preferred, because it is less toxic and, like Au(CN)2 , AuBr4 is a water soluble anion. Thus, in aqueous HBR, the metal, e.g., gold, can be etched by applying a sufficiently oxidizing potential where gold is electrolytically dissolved:
  • [0000]

  • [0031]
    Wired Enzyme Layer: In the sensing enzyme-containing layer, glucose oxidase may be substituted with other redox enzymes to measure other relevant clinical compounds. For example, lactate oxidase may be used for the in vivo detection of lactate, important in determining if an organ is receiving sufficient oxygen through the blood.
  • [0032]
    Useful redox polymers and methods for producing the sensing layer are described, for example, in U.S. Pat. Nos. 5,264,104; 5,356,786; 5,262,035, and 5,320,725. Additional redox polymers include, for example, poly(1-vinyl imidazole); poly(4-vinyl pyridine); or copolymers of 1-vinyl imidazole such as poly (acrylamide co-1-vinyl imidazole) where the imidazole or pyridine complexes with [Os (bpy)2Cl]+/2+; [Os (4,4′-dimethyl bipyridine)2Cl]+/2+; [Os (4,4′-dimethyl phenanthroline)2Cl-]+/2+; [Os (4,4′-dimethyoxy phenanthroline)2Cl]+/2+; and [Os (4,4′-dimethoxy bipyridine)2Cl]+/2+; to imidazole rings. The imidazole ring compounds are preferred because their complexes have more reducing redox potentials, i.e., closer to that of the SCE potential. At these more reducing potentials, the rate of electrooxidation of interferants and the current generated thereby.
  • [0033]
    Barrier Layer The polymeric barrier layer is electrically insulating and limits diffusion of glucose through to the sensing layer. It may be formed, for example, by crosslinking a polyallylamine (PAL) with a polyaziridine (PAZ). Alternatively, PAL may be replaced wholly or in part with a zwitterionic polymer obtained by quaternizing poly(vinylpyridine) with bromoacetate and dialyzing against 0.15M NaCl or by a polyanion such as a polysulfonic acid.
  • [0034]
    The barrier layer may contain a polyanionic polymer, in which the rate of permeation of anionic interferants such as ascorbate and urate is slowed. This layer may also contain a polycation that enhances the retention of the polyanion by electrostatic bonds and improves wetting by the biocompatible layer.
  • [0035]
    Interference Eliminating Layer: As described above, this layer is optional, in that it is not required when a redox polymer having a more reducing potential is used, such as PVI15-dmeOs (Ohara et al., Analytical Chemistry, 1994, 64:2451-2457). At operating potentials of approximately −0.10 to +0.25 for the glucose biosensor, the rate of electrooxidation of interferants such as ascorbate, urate and acetaminophen is very slow relative to that of glucose through its physiological concentration range.
  • [0036]
    When a separate interferant eliminating layer is used, it preferably contains a peroxidase enzyme which may or may-not be pre-activated. Such interferant eliminating layers are disclosed, for example, in U.S. Pat. No. 5,356,786, which discloses the structure and function of interferant eliminating biosensors. The glucose biosensor preferably contains lactate oxidase (LOX) in combination with peroxidase in the interferant eliminating layer. However, for biosensors used to detect lactate, glucose oxidase would be used with peroxidase. In a similar manner, the enzyme composition of the interferant eliminating layer may be altered for a specified function.
  • [0037]
    Biocompatible Layer: In general, the biocompatible layer is comprised of hydrogels, e.g., polymeric compositions which contain more than about 20% by weight of water when in equilibrium with a physiological environment such as living tissue or blood. An example is crosslinked poly(ethylene oxide), e.g., poly(ethylene oxide) tetraacrylate. The polymeric compositions must be non-toxic and compatible with living systems.
  • [0038]
    Method for making multi-layered recessed biosensors: Insulated non-corroding metal or carbon wires that have been etched as described above to contain a recess at the tip, are placed in a block that serves as an X-Y positioner. The wires vertically traverse the block and are held in place, e.g., by pressure. The blocks with the wires can be formed of elements, each element having multiple half-cylinder grooves running vertically. The wires are placed in these grooves and the elements are assembled into the block using screws. For example, the block may be formed of aluminum having equally spaced holes, (900 for a 30×30 array of wires), each hole to contain one wire. The block is positioned under a fixed micronozzle that ejects a fluid in to the recess of the insulated wire.
  • [0039]
    To reduce the requirement of precision in the positioning of the block and the micronozzle, the nozzle is electrically charged, with the wire having an opposite charge, or the wire being grounded or at least having a potential such that there is a potential difference between the nozzle and the wire. Because the nozzle is charged, the microdroplets it ejects are also charged with the same type of charge (positive or negative) as the nozzle. The higher the potential on the nozzle (e.g., versus ground potential), the higher the charge on the ejected microdroplets. If the tip of the wire to be coated is at ground potential or has a charge of the opposite type, the charged microdroplets are guided into the recess to deposit on the electrode, even if the jet of microdroplets is not vertical, i.e., even if the micronozzle is not precisely aligned above the wire's tip.
  • [0040]
    Furthermore, the higher the electrical potential on the nozzle (relative to ground) the greater the charge on the ejected microdroplet. When the charge is high enough, the droplet breaks up into two or more smaller droplets because of electrostatic repulsion of charges on the droplet. Thus, the very small droplets all “drift” (drift meaning transport assisted by an electrical field) to the recessed electrode surface and are collected on it, even if they did not originate in a nozzle precisely aligned with the electrode.
  • [0041]
    This coating method is useful in making any small biosensor, not only those in recessed zones.
  • [0042]
    Clinical Use of the Recessed Biosensors:
  • [0043]
    The recessed biosensors of the present invention have sufficient sensitivity and stability to be used as very small, subcutaneous biosensors for the measurement of clinically relevant compounds such as glucose and lactate. The electrodes accurately measure glucose in the range of about 2-30 μM and lactate in the range of about 0.5-10 mM. One function of the implanted biosensor is to sound an alarm when, for example, a patient's glucose concentration is too low or too high. When pairs of implanted electrodes are used, there are three situations in which an alarm is triggered: low glucose concentration, high glucose concentration; sensor malfunction as determined by a discrepancy between paired readings of the two sensors. A discrepancy sufficient to trigger the alarm may be, for example more than two or three times the standard deviation persisting for a defined period, e.g., not less than ten minutes. Such a system may be useful in sleeping patients, and also in emergency and intensive care hospital rooms, where vital functions are continuously monitored.
  • [0044]
    Another function of the inventive biosensors is to assist diabetics in maintaining their blood glucose levels near normal. Many diabetics now maintain higher than normal blood glucose levels because of danger of coma and death in severe hypoglycemia. However, maintaining blood glucose levels substantially, e.g., approximately 40% or more above normal leads to retinopathy and blindness as well as to kidney failure. Use of the subcutaneous biosensors to frequently, if not continuously, monitor glucose concentrations is desirable so that glucose concentrations can be maintained closer to an optimum level.
  • [0045]
    The subcutaneous biosensors can be used to measure the rate of rise and decline of glucose concentrations after a meal or the administration of glucose (e.g., a glucose tolerance test). The sensors are also useful in feedback loops for automatic or manually controlled maintenance of glucose concentrations within a defined range. For example, when used in conjunction with an insulin pump, a specified amount of insulin is delivered from the pump if the sensor glucose reading is above a set value.
  • [0046]
    In all of these applications, the ability to promptly confirm that the implanted sensor reading is accurate is essential. Prompt confirmation and rapid recalibration are possible only when one-point calibration is valid. Generally, even if a sensor's response is linear through the relevant concentration range, calibration requires at least two blood or fluid samples, withdrawn from the patient at times when the glucose concentration differs. It usually takes several hours for the glucose concentration to change sufficiently to validate proper functioning by two-point calibration. The ability to confirm and recalibrate using only one point is thus a highly desirable feature of the present invention.
  • [0047]
    Redundant sensors (e.g., at least two) are preferred in the clinical application of the subcutaneous biosensors. Such redundancy permits signaling of failure of any one sensor by recognition of an increase in the discrepancy between the readings of the sensors at one time point, e.g., more than two standard deviations apart. The redundant sensors may be implanted near each other or at remote sites.
  • [0048]
    It is preferred that the biosensors be implanted in subcutaneous tissue so as to make the sensor relatively unobtrusive, and at a site where they would not be easily dislodged, e.g., with turning or movement. It is also preferred, when readings are not corrected for temperature (which they generally are) that the sensors be implanted where they are likely to be at body temperature, e.g., near 37° C., and preferably covered by clothing. Convenient sites include the abdomen, inner thigh, arm.
  • [0049]
    Although we describe here continuous current measurement for assaying glucose, the electrical measurement by which the glucose concentration is monitored can be continuous or pulsed. It can be a current measurement, a potential measurement or a measurement of charge. It can be a steady state measurement, where a current or potential that does not substantially change during the measurement is monitored, or it can be a dynamic measurement, e.g., one in which the rate of current or potential change in a given time period is monitored. These measurements require at least one electrode in addition to the sensing electrode. This second electrode can be placed on the skin or can be implanted, e.g., subcutaneously. When a current is measured it is useful to have a potentiostat in the circuit connecting the implanted sensing electrode and the second electrode, that can be a reference electrode, such as an Ag/AgCl electrode. When a current is measured the reference electrode may serve also as the counter electrode. The counter electrode can also be a separate, third electrode, such as a platinum, carbon, palladium or gold electrode.
  • [0050]
    In addition to implanting the sending electrode in the body, fluid from the body, particularly fluid from the subcutaneous region, can be routed to an external sensor. It is preferred in this case to implant in the subcutaneous region a microfiltration giver and pull fluid to an evacuated container, the fluid traversing a cell containing the sensing electrode. Preferably this cell also contains a second electrode, e.g., a reference electrode which may serve also as a counter electrode. Alternatively, the reference and counter electrodes may be separate electrodes. In coulometric measurements only two electrodes, the sensing electrode and the counter electrode are required. The flow of body fluid may be pulsed or continuous. Other than an implanted microfiltration fiber, also a microdialysis fiber may be used, preferably in conjunction with a pump.
  • [0051]
    Increased Stability of the Biosensors:
  • [0052]
    To increase the stability and useful life of the inventive biosensors, it is advantageous to use intrinsically more stable enzymes and redox polymers. However, even if the enzyme and redox polymer degrade in the glucose electrooxidation process by which the signal (current) is generated, it is possible to greatly extend the useful life of the implanted electrodes and reduce the frequency of their required recalibration after implantation.
  • [0053]
    A simple measure by which the life of the implanted electrodes can be extended and the frequency of their required recalibration reduced involves turning the electrodes “on” by applying a bias, i.e., a potential, only during the period of measurement, then turning the biasing potential off or reducing it, so that a lesser current will flow. It is generally sufficient to perform only one measurement every five or even ten minutes, or longer, because glucose concentrations do not change abruptly.
  • [0054]
    Another measure is to lower the glucose flux to the sensing layer much as possible, consistent with maintaining adequate sensitivity and detectivity. Reduction of the glucose flux to the sensing layer reduces the current. Therefore, even though this stabilizes the electrodes, i.e., slows the loss in sensitivity, the flux dependent current must not be excessively reduced. Usually a current of 3-5 nA at 2 mM glucose concentration is adequate. When the glucose flux is lowered by using one or more glucose-flux reducing polymer slayers, such as the PAL/PAZ layer, the lifetime of the sensor is increased.
  • EXAMPLES Example 1 Electrode Preparation
  • [0055]
    Electrodes were made of a polyamide-insulated 250 μm diameter gold wire, having an outer diameter (O.D.) of 290 μm (California Fine Wire Co., Grover City, Calif.). Heat shrinkable tubing (RNF 100 3/64” BK and 1/16” BK, Thermofit®, Raychem, Menlo Park, Calif.) and a two component silver epoxy (Epo-tek H2OE; Epoxy Tech, Inc., Billerica, Mass.) were used for electrode preparation.
  • [0056]
    The glucose sensing layer was made by crosslinking a genetically engineered glucose oxidase (rGOX) (35% purity, Chiron Corp., Emeryville, Calif.) with a polymer derived of poly(vinylimidazole) (PVI), made by complexing part of the imidazoles to [Os(bpy)2Cl]+/2+. The resulting redox polymer, termed PVI-Os, was synthesized according to a previously published protocol. (Ohara et al., 1993, Anal. Chem., 65:24). Poly(ethylene glycol) diglycidyl ether 400 (PEDGE; Polysciences, Warrington, Pa.) was used as the crosslinker.
  • [0057]
    The barrier layer between the sensing and interference-eliminating layers was made of polyallylamine (PAL; Polysciences) crosslinked with a polyfunctional aziridine (PAZ) (XAMA-7; Virginia Chemicals, Portsmouth, Va.).
  • [0058]
    The interference-eliminating layer was prepared by co-immobilizing horseradish peroxidase (HRP) type VI (Cat. No. P-8375, 310 U/mg, denoted herein as HRP-VI, Sigma, St. Louis, Mo.) and HRP for immunological assay (No. 814407, min 1000 U/mg, denoted HRP-BM, Boehringer-Mannheim, Indianapolis, Ind.) with lactate oxidase from Pediococcus sp. (Cat. No. 1361, 40 U/mg denoted LOX, Genzyme, Cambridge, Mass.) and a recombinant microbial source (Cat. No. 1381 denoted rLOX, Genzyme). Co-immobilization was performed using sodium periodate (Cat. No. S-1147, Sigma) according to the methods described in Maidan and Heller, 1992, Anal. Chem. 64:2889-2896.
  • [0059]
    The biocompatible layer was made of 10% aqueous poly(ethylene oxide) tetraacrylate (PEO-TA). To form the photocrosslinkable polymer, PEO was acrylated by reaction with acryloyl chloride. The 18,500 g/mol PEO (Polysciences) is a tetrahydroxylated compound by virtue of two hydroxyl groups on a bisphenol A bisepoxide that linked two .alpha., .omega.-hydroxy-terminated 9,000 g/mol PEO units. Acryloyl chloride (Aldrich, Milwaukee, Wis.) in a 2 to 5 molar excess was used to acrylate the polymer (10% w/v PEO in benzene). Triethylamine (Mallinkrodt, Paris, Ky.) was used as a proton acceptor equimolar with theacryloyl chloride.
  • [0060]
    Other chemicals used were bovine serum albumin (BSA) fraction V (Cat. No. A-2153), BSA, ascorbic acid, uric acid, 4-acetaminophenol, L(+)=lactic acid, and hydrogen peroxide 30%, all from Sigma. All chemicals were used as received. Solutions (if not otherwise specified) were made with distilled, deionized water. Glucose monitoring was performed in buffer, in bovine serum (Sigma, Cat. No. S-6648) containing antibiotic-antimycotic solution (Sigma, Cat. No. A-8909) at 37° C. and in rats.
  • [0061]
  • [0062]
    In making the recessed gold electrodes, a potentiostat/galvanostat (PAR Model 173, Princeton Applied Research, Princeton, N.J.) operated in a galvanostatic mode, and a sonicator (Fisher scientific, Pittsburgh, Pa.) were used. Cyclic voltammograms were recorded with a potentiostat (PAR Model 273A) and a conventional electrochemical cell having a Pt wire counter and a SCE reference electrode and were evaluated with PAR 270 software. Glucose signals were monitored with a bipotentiostat (Biometra EP 30) and a two channel strip-chart recorder. The recessed electrodes were coated under a microscope (Bausch & Lomb) using a micromanipulator (Narishige, Seacliff, N.Y.). The micropipettes were pulled with a micropipette puller (Narishige). Temperature was controlled with an isothermal circulator (Fisher Scientific).
  • [0063]
    Electrode Preparation:
  • [0064]
    Five cm lengths of polyamide insulated gold wire were cut with a sharp razor blade. Electrical contact was made at one end with silver epoxy to an insulated stainless steel wire and the junction was covered with insulating heat shrinkable tubing. The recess forming electrochemical etching process was carried out in 10 ml of 3M potassium cyanide, with the gold wire as the working electrode and a platinum or gold wire as the counter electrode. The wires were placed in contact with the bottom of the beaker, all electrodes being equidistant from the counter electrode. The beaker was sonicated during the etching procedure. The ends of the gold wires were bent upwards, so that agitation by the sonicator caused the oxygen bubbles formed during the etching process to rise and escape. The electrodes were then thoroughly washed and immersed in water for 30 minutes.
  • [0065]
    A recess 6, i.e., channel, in a polyamide insulated gold wire 2 is formed by electrochemical etching of the gold under galvanostatic control. By controlling the charge, the total amount of gold electrooxidized and dissolved as Au(CN)2 is defined.
  • [0066]
    When the conditions were set so that the CN—transport into the channel and the Au(CN)2—transport out of it are not rate limiting, (e.g., sonicated bath and high concentration of potassium cyanide, at least approximately 0.2M, and preferably 3M), a flat gold wire surface is produced at the bottom of channels with aspect ratios of 0.5 to 2.0. Thus, when the CN—concentration is high enough and the wires are ultrasonically vibrated, the tips of gold wires are flat. Passage of 1.5 coulombs per electrode at 8 mA current produced approximately 125 μm deep cavities or channels. At theoretical efficiency for one-electron oxidation, 3.08 mg of gold would have been etched. The amount of gold actually etched was only 0.076 mg, showing significant CN—or water oxidation.
  • [0067]
    Nevertheless, the process is reproducible, accurate and fast with 20 electrodes being processed in each batch in less than five minutes. The recess-forming procedure was highly reproducible, with a deviation of +/−10 μm found (using an objective micrometer) for a batch of 30 recessed electrodes. Before coating, the electrodes were examined under a microscope for flatness of the gold surface and correct depth.
  • [0068]
    FIG. 1 shows a schematic side view in cross-section of an electrode of the present invention, showing the gold wire 2, insulating coating 4, and recess or channel 6. The recessed gold surfaces were coated by filling of the cavities or channels 6 with aqueous solutions containing the crosslinkable components of the different layers, and their crosslinkers. The solutions were introduced under a microscope with a micropipette (connected to a microsyringe by polyethylene tubing and shrink tubing), using a micromanipulator. After application of each of the individual layers, the electrodes were cured overnight at room temperature, in air.
  • [0069]
    Electrode Structure:
  • [0070]
    The electrodes were prepared by sequentially depositing four layers within the recess or channel 6. The layers were: the sensing layer 8, the insulating layer 10, the interference-eliminating layer 12 and the biocompatible layer 14. The sensing layer, containing “wired” redox enzyme is positioned adjacent to and in contact with the gold wire 2. The insulating layer 10 is positioned between the sensing layer 8 and the peroxidase-based interferant-eliminating layer 12. The biocompatible layer 14 fills the remaining space in the recess 6 and is in contact with the environment outside the electrode. The thin polymer layers are well protected by containment within the polyamide sleeve 4.
  • [0071]
    The sensing layer 8 was made by “wiring” rGOX to the gold electrode through a redox hydrogel to which the enzyme was covalently bound. The electrodes were prepared as follows: 10 mg/ml solutions were made from
      • 1. the PVI-Os redox polymer in water,
      • 2. the crosslinker, PEGDGE, in water, and
      • 3. the enzyme, rGOX, in a 10 mM HEPES solution adjusted to pH 8.15.
  • [0075]
    A redox hydrogel was formed by mixing the three solutions so that the final composition (by weight) was 52% redox polymer, 35% enzyme and 13% crosslinker.
  • [0076]
    The insulating layer 10 prevented electrical contact between the redox hydrogel and the interference eliminating enzymes (HRP and LOX). PAL:PAZ was used as the insulating material. The film was deposited from a solution obtained by mixing in volume ratio of 1/1, ˝ or ⅓, a PAL solution (4.5 mg in 100 mM HEPES buffer at pH 7.0) and a freshly prepared PAZ solution (30 mg/ml). The PAZ solution was used within 15 minutes of preparation.
  • [0077]
    The interference-eliminating layer 12 was prepared according to a previously published protocol, Maidan and Heller, 1992, Anal. Chem., 64:2889-2896. 50 μl of a 12 mg/ml freshly prepared sodium periodate solution was added to 100 μl of a solution containing 20 mg/ml HRP(HRP-VI or HRP-BM) and 100 mg/ml LOX (LOX or rLOX) in 0.1 M sodium bicarbonate and the mixture was incubated in the dark for two hours. Alternatively, the oxidation of HRP could be carried out prior to adding LOX and crosslinking.
  • [0078]
    The biocompatible layer 14 films were photocrosslinked by exposure to UV light (UVP, Inc., San Gabriel, Calif.; Blak-Ray; spectral peak at 360 nM UV irradiance at the sample 200 mW/cm2) for one minute. The initiator used was 2,2 dimethoxy-2-phenylacetophenone (Aldrich). A solution of 300 mg/ml of the initiator in 1-vinyl-2-pyrrolidinone (Aldrich) was added to the prepolymer mixtures. Approximately 30 μl of the initiator solution was added per ml of 10% w/w aqueous solution of the tetraacrylated PEO. The prepolymers were crosslinked in situ inside the recess of the electrode. The films were prepared by filling the recess with the prepolymer solution twice and exposing the electrode to the UV light source after each time the cavity was filled.
  • [0079]
    In vitro Testing of Electrodes:
  • [0080]
    In vitro experiments were carried out in batch fashion at 250 and 37° C., using a conventional three electrode electrochemical cell with the enzyme-modified gold wire as the working electrode, a platinum wire as the counter electrode and a saturated calomel reference electrode (SCE). The electrolyte was a 20 mM phosphate buffered-saline solution containing 0.15 M NaCl at pH 7.15. Experiments in serum were performed at 37° C., adding 100 μL antibiotic-antimycotic solution to 10 ml serum. Phosphate buffered-saline and serum were agitated during the experiments. The working potential was +0.3 V versus SCE for experiments with the PVI-Os polymers.
  • [0081]
    Structure and Performance: The depth c of the channel 6 and the thickness of the polymer layers in it controls the mass transport, i.e., flux of glucose, to the sensing layer. By controlling these parameters, the apparent Michaelis constant (Km) is adjusted to about 20-30 mM glucose. The polyimide wall 4 of the channel 6 also protects the four polymer and polymer/enzyme layers 8, 10, 12, 14 against mechanical damage and reduces the hazard of their loss in the body. Because the glucose electrooxidation current is limited by glucose mass transport through the recess 16 and its polymer films 8, 10, 12, 14, rather than by mass transport to the tissue-exposed tip 16, the current is practically insensitive to motion. Evidently, the electrooxidation rate of glucose in the recessed sensing layer 8 is slower than the rate of glucose diffusion to the channel's outer fluid contacting interface.
  • [0082]
    PVI5-Os is preferred as the “wire” of the sensing layer when an interference eliminating layer of HRP and LOX is used, but not in the absence of this layer, i.e., when redox polymers with more reducing redox potential are preferred. The subscript (5) is used to indicate that, on the average, every fifth vinylimidazole mer carries an electron-relaying osmium center. Use of electrodes formed with PVI5-Os and PVI3-Os (every third 1-vinylimidazole mer carrying an osmium center) are compared in FIG. 2, and show higher current density of glucose electrooxidation on electrodes made with PVI5-Os (open triangle) than on those made with PVI3-Os (filled triangles).
  • [0083]
    Depth of the recess and the sensing layer: Channels of 125, 250, and 500 μm depth, were investigated to assess the dependence of the current on the depth of the recess (FIG. 3), with the total amount of PVI5-Os and rGOX being kept constant. Much of the loss in current in the deeper cavities resulted not from reduced glucose mass transport, but from adsorptive retention of part of the enzyme and polymer on the polyamide wall when microdrops of the component solutions were introduced into the recess in the process of making the electrodes. Through repeated rinsing with water, some of the adsorbed polymer and enzyme on the walls were washed onto the electrode surface, increasing the current. The highest currents were seen after five washings. When the thickness of the sensing layer was increased through increasing the number of coatings (FIG. 4) the ratio of current to charge required to electroreduce or electrooxidize the redox polymer in the sensing layer reached a maximum, then dropped. For the preferred 125 μm recess, 10 coatings, producing an approximately 13 Am thick wired-rGOX sensing layer, yielded sensors that had the desired characteristics for in vivo use.
  • [0084]
    The insulating layer: This layer electrically insulates the redox enzymes of the interference eliminating layer (HRP and LOX) from the “wired” rGOX layer and limits the glucose flux to the sensing layer, thereby extending the useful life of the electrode. PAL crosslinked with PAZ, forming a polycationic network at pH 7.09 is preferred. The best results, i.e., best stability of current outputs, were obtained using 1:2 PAL:PAZ (FIG. 5), with three coatings applied to form an approximately 7 μm thick crosslinked film.
  • [0085]
    The interference eliminating layer: Interferants, particularly ascorbate, urate, and acetaminophenol, are oxidized in the third layer, containing LOX and HRP. In this layer, lactate, the typical concentration of which in blood is 1 mM, reacts with O2 to form H2O2 and pyruvate. H2O2, in the presence of HRP, oxidizes ascorbate, urate, and acetaminophenol, being reduced to water. The preferred coimmobilization process involved two separate steps: periodate oxidation of oligosaccharide functions of HRP to aldehydes, followed by mixing with LOX and formation of multiple Schiff bases between HRP-aldehydes and LOX amines (e.g. lysines) and between HRP aldehydes and amines. The thickness of the interference eliminating layer is approximately 85 μm and is made by applying successive coatings, e.g., about six coatings. FIG. 6 shows that electrooxidizable interferants were eliminated in the presence of lactate at physiological levels. LOX slowly lost its activity in the crosslinked HRP-LOX layer. This led to degradation of the ability of the layer to eliminate interferants. After 36 hours of operation at 37° C., a measurable current increment was noted when enough ascorbate was added to produce a 0.1 mM concentration.
  • [0086]
    The biocompatible layer: A preferred biocompatible layer consists, for example, of photocrosslinked tetraacrylated 18,500 Da poly(ethylene oxide) (Pathak et al., 1993, J. Am. Chem. Soc., 114:8311-8312). The thickness of this layer, made by sequential photo-crosslinking of two coatings, is about 20 μm. One minute UV exposure required for the photocrosslinking process reduced the sensitivity by 16+/−2%.
  • Example 2 In Vivo Use of Sensor
  • [0087]
    The objective of this experiment was to establish the validity of a one-point in vivo calibration. Two sensors were simultaneously implanted subcutaneously in a rat, one on the thorax, the second between the scapulae. To make the difference between the blood sampled and the subcutaneous fluid proved with the sensors as extreme as possible, i.e., to probe whether the one-point calibration holds even if the organs sampled are different and the sampling sites are remote, blood was withdrawn from the tail vein. Blood glucose levels were periodically measured in withdrawn samples, while the absolute uncorrected sensor current output was continuously monitored.
  • [0088]
    In vivo experiments (6-10 hours) were carried out in 300 g male Sprague-Dawley rats. The rats were fasted overnight and prior to the experiment were anaesthetized with an intraperitoneal (i.p.) injection of sodium pentobarbital (65 mg/kg rat wt). An i.p. injection of atropine sulfate (166 mg/kg rat wt) was then administered to suppress respiratory depression. Once the rat was anaesthetized, a portion of the rat's abdomen was shaved, coated with a conductive gel, and an Ag/AgCl surface skin reference electrode was attached. This electrode served also as the counter electrode. Sensors were then implanted subcutaneously using a 22 gauge Per-Q-Cath Introducer (Gesco International, San Antonio, Tex.) on the rat's thorax, or subcutaneously in the intrascepular area through a small surgical incision. The sensors were taped to the skin to avoid sensor movement. The sensors, along with the reference electrode, were connected to an in-house built bipotentiostat. The operating potential of the sensors was 0.3 V vs. Ag/AgCl, with the Ag/AgCl electrode serving as both the reference counter electrode. Sensor readings were collected using a data logger (Rustrak Ranger, East Greenwich, R.I.) and at the end of the experiment were transferred to a computer. During the experiment, the rat's body temperature was maintained at 37° C. by a homeostatic blanket. The sensors were allowed to reach a basal signal level for at least one hour before blood sampling was started. Blood samples were obtained from the tail vein and all blood samples were analyzed using a glucose analyzer (YSI, Inc., Yellow Springs, Ohio; Model 23A).
  • [0089]
    Approximately thirty minutes after the start of blood sampling, an i.p. glucose infusion was started using a syringe pump (Harvard Apparatus, South Natick, Mass.) at a rate of 120 mg glucose/min kg rat wt. The glucose infusion was maintained for approximately one hour.
  • [0090]
    As seen in FIG. 7, at 410 min the current dropped precipitously. Such a drop was observed in other measurements with subcutaneously implanted electrodes between 400 and 600 min, but was never observed in electrodes operated in buffer at 37° C. When the failed electrodes were withdrawn and retested in buffer, most of their original sensitivity was found to be intact. The cause for this apparent deactivation was failure of the counter/reference Ag/AgCl electrode on the rat's skin to make good electrolytic contact, and was not due to any failure of the implanted sensor. Using an arbitrarily chosen point to calculate a calibration curve for each electrode, i.e., one blood glucose level determination and one current measurement to establish the scales, all the data from FIG. 7 were plotted in a Clarke-type, (Clarke et al., 1987, Diabetes Care, 5:622-627) clinical grid (FIG. 8), without further correction. In this analysis, points falling in region A of the grid are considered clinically accurate, while those in region B are considered clinically correct. Points falling in region C are not correct, but would not lead to improper treatment. Points in regions D and E are incorrect and if treatment would rely on these, it would be improper.
  • [0091]
    All of the points, from both electrodes, were in regions A and B, with 43 of the 48 points being in region A. The three points in region B near 100 mg/dl glucose, for the electrode implanted between the scapulae, were the last three points of the experiment, at about 410 min. Notwithstanding the failure mode at 400-600 min because of poor electrolytic contact of the counter/reference electrode with the skin and failure after 36 hours by deactivation of the lactate oxidase, resulting in loss of interference elimination, one-point calibration is shown here to be practical. After such calibration, the readings of the subcutaneous sensors provide, without any correction, clinically useful estimates of blood glucose levels.
  • [0092]
    FIG. 9 shows the distribution of all possible correlations obtained when each of the 24 glucose analyses was used for single point calibration of either implanted electrode. There are 2×24×24=1152 points in the distribution. Of these, 78% are in region A, 15% are in region B, 1% are in region C, 6% are in region D, and no points are in region E.
  • [0093]
    In FIG. 10, we tested for the improvement of the single point calibration through using redundant electrodes. First, the readings of electrode A were normalized with respect to those of electrode B by multiplying each reading by the average output of electrode B divided by the average output of electrode A. Next the standard deviation was calculated for the differences between the 24 sets of readings of implanted electrode B and corrected readings of implanted electrode A. Then, all those sets of readings that differed by more than the standard deviation were rejected. The number of sets was reduced thereby from 24 to 11; 82% of the points were in region A, 17% in region B, 1% in region D, and no points in regions C and E. The distribution demonstrates that the sensors can be calibrated through a single independent measurement of the glucose concentration in a withdrawn blood sample. They also demonstrate the improvement in clinical accuracy resulting from the use of redundant subcutaneous sensors. The selection of those data points that differed by less than the standard deviation for the entire set led to a six fold reduction in the probability of clinically erring in a decision based on readings of the implanted sensors.
  • [0094]
    Stability and Other Characteristics:
  • [0095]
    In order to improve the stability, more thermostable recombinant GOX, (rGOX; Heller, 1992, J. Phys. Chem., 96:3579-3587) rather than GOX is used in the sensor and glucose transport is reduced to make the sensor current diffusion, not enzyme turnover, limited. The glucose flux is attenuated by the three outer layers and the sensing layer itself. Because the sensing layer contains a large excess of glucose oxidase, its activity greatly exceeds that needed for electrooxidizing the attenuated glucose flux, and the sensor's stability is improved.
  • [0096]
    The stability can be tested by methods known, for example, tested in the presence of 0.1 mM ascorbate in 10 mM glucose at 37° C. The current output of a typical optimized electrode was about 35 nA and the apparent Km, derived from an Eadie-Hofstee plot, was about 20 mM (Table 1). The 10-90% response time was approximately one minute.
  • [0097]
    As expected, and as can be seen in FIG. 5, with thinner films the glucose mass transport was increased, i.e., the current was higher, while for thicker films the stability was improved. Because of the high sensitivity of thin sensing film (approximately 1 μm) electrodes (less than 10−2 A cm−2 M−1), an order of magnitude decrease in sensitivity could be traded for stability, while the currents remained high enough to be easily measured.
  • [0098]
    As seen in FIG. 5, the sensitivity of the stabilized sensors does not change by more than +5% for 72 hours of operation at 37° C. After a small initial decrease in sensitivity, it increased to a maximum after 40 hours and the final 72 hour sensitivity was almost identical with the initial.
  • [0099]
    The characteristics of the electrodes of the present invention are summarized in Table 1. Each entry represents an average value for five tested electrodes. Baseline currents are typically less than 0.5 nA and the noise less than 10 pA. The currents observed throughout the physiological glucose concentration range (2-20 mM) exceed the noise equivalent current by at least a factor of 100. The apparent Km is 20 mM, and the 10% to 90% response time is, for aged electrodes, about 90 seconds at the lowest physiologically relevant glucose concentration (2 mM) and 20 seconds at the highest (20 mM).
  • [0100]
    The baseline of nil at 0 mM glucose is stable for 36 hours in the presence of 0.1 mM ascorbate. The stability observed and the existence of a valid zero-point in the presence of interferants suggest that the sensor can be used in vivo for 72 hours and tested/recalibrated in vivo through a single point calibration, i.e., by withdrawing only a single sample of blood for independent analysis.
  • [0000]
    TABLE 1
    Km app (mM) Km app (mM) Variance
    i (nA) j (μA/cm2) EH LB tr (s) (%)
    33.9 69.1 18.5 33.4 30-90 5.0
    i is the current measured at 37° C. and at 10 mM glucose concentration
    j is the current density measured at 37° C. at 10 mM glucose concentration
    KM app is the apparent Michaelis-Menten coefficient determined from an electrochemical Eadie-Hoffstee (EH) or Lineweaver-Burk (LB) plot
    tr is the 10-90% rise time, 90 s for 2 mM and 30 s for 20 mH glucose concentration.
    Current Variance is the maximum deviation from the mean value, measured during the 72 hour test, conducted in 10 mM glucose in the presence of interferants. The current was continuously monitored at 37° C.
  • [0101]
    The foregoing examples are designed to illustrate certain aspects of the present invention. The examples are not intended to be comprehensive of all features and all embodiments of the present invention, and should not be construed as limiting the claims presented herein.
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3776832 *10 Nov 19704 Dec 1973Energetics ScienceElectrochemical detection cell
US3926760 *28 Sep 197316 Dec 1975Du PontProcess for electrophoretic deposition of polymer
US3991770 *23 Dec 197516 Nov 1976Leveen Harry HMethod for treating benign and malignant tumors utilizing radio frequency, electromagnetic radiation
US4008717 *5 Mar 197622 Feb 1977The Johns Hopkins UniversitySystem for continuous withdrawal and analysis of blood
US4055175 *7 May 197625 Oct 1977Miles Laboratories, Inc.Blood glucose control apparatus
US4059406 *12 Jul 197622 Nov 1977E D T Supplies LimitedElectrochemical detector system
US4076596 *7 Oct 197628 Feb 1978Leeds & Northrup CompanyApparatus for electrolytically determining a species in a fluid and method of use
US4129128 *23 Feb 197712 Dec 1978Mcfarlane Richard HSecuring device for catheter placement assembly
US4172770 *27 Mar 197830 Oct 1979Technicon Instruments CorporationFlow-through electrochemical system analytical method
US4178916 *26 Sep 197718 Dec 1979Mcnamara Elger WDiabetic insulin alarm system
US4184429 *29 Jan 197622 Jan 1980Max Datwyler & Co.Constant bevel doctor blade and method and apparatus using same
US4240438 *2 Oct 197823 Dec 1980Wisconsin Alumni Research FoundationMethod for monitoring blood glucose levels and elements
US4247297 *23 Feb 197927 Jan 1981Miles Laboratories, Inc.Test means and method for interference resistant determination of oxidizing substances
US4352960 *30 Sep 19805 Oct 1982Baptist Medical Center Of Oklahoma, Inc.Magnetic transcutaneous mount for external device of an associated implant
US4356074 *25 Aug 198026 Oct 1982The Yellow Springs Instrument Company, Inc.Substrate specific galactose oxidase enzyme electrodes
US4365637 *29 Sep 198028 Dec 1982Dia-Med, Inc.Perspiration indicating alarm for diabetics
US4366033 *11 Apr 197928 Dec 1982Siemens AktiengesellschaftMethod for determining the concentration of sugar using an electrocatalytic sugar sensor
US4418148 *5 Nov 198129 Nov 1983Miles Laboratories, Inc.Multilayer enzyme electrode membrane
US4425920 *24 Oct 198017 Jan 1984Purdue Research FoundationApparatus and method for measurement and control of blood pressure
US4427770 *14 Jun 198224 Jan 1984Miles Laboratories, Inc.High glucose-determining analytical element
US4431004 *27 Oct 198114 Feb 1984Bessman Samuel PImplantable glucose sensor
US4477314 *20 Jul 198316 Oct 1984Siemens AktiengesellschaftMethod for determining sugar concentration
US4478976 *20 Sep 198223 Oct 1984Basf AktiengesellschaftWater-insoluble protein material, its preparation and its use
US4484987 *19 May 198327 Nov 1984The Regents Of The University Of CaliforniaMethod and membrane applicable to implantable sensor
US4494950 *19 Jan 198222 Jan 1985The Johns Hopkins UniversityPlural module medication delivery system
US4543955 *1 Aug 19831 Oct 1985Cordis CorporationSystem for controlling body implantable action device
US4545382 *22 Oct 19828 Oct 1985Genetics International, Inc.Sensor for components of a liquid mixture
US4552840 *2 Dec 198212 Nov 1985California And Hawaiian Sugar CompanyEnzyme electrode and method for dextran analysis
US4560534 *2 Nov 198324 Dec 1985Miles Laboratories, Inc.Polymer catalyst transducers
US4571292 *12 Aug 198218 Feb 1986Case Western Reserve UniversityApparatus for electrochemical measurements
US4619754 *8 Mar 198328 Oct 1986Ajinomoto Company IncorporatedChemically modified electrodes and their uses
US4619793 *26 Jul 198428 Oct 1986Ciba-Geigy CorporationMethod of producing annealed polyvinyl alcohol contact lens
US4633878 *10 Apr 19846 Jan 1987Guiseppe BombardieriDevice for the automatic insulin or glucose infusion in diabetic subjects, based on the continuous monitoring of the patient's glucose, obtained without blood withdrawal
US4637403 *14 Jun 198520 Jan 1987Garid, Inc.Glucose medical monitoring system
US4699157 *27 Aug 198513 Oct 1987Electro-Catheter CorporationPacing catheter and method of making same
US4703756 *6 May 19863 Nov 1987The Regents Of The University Of CaliforniaComplete glucose monitoring system with an implantable, telemetered sensor module
US4717673 *19 Nov 19855 Jan 1988Massachusetts Institute Of TechnologyMicroelectrochemical devices
US4721601 *23 Nov 198426 Jan 1988Massachusetts Institute Of TechnologyMolecule-based microelectronic devices
US4721677 *7 May 198726 Jan 1988Children's Hospital Medical CenterImplantable gas-containing biosensor and method for measuring an analyte such as glucose
US4726378 *11 Apr 198623 Feb 1988Minnesota Mining And Manufacturing CompanyAdjustable magnetic supercutaneous device and transcutaneous coupling apparatus
US4726716 *21 Jul 198623 Feb 1988Mcguire Thomas VFastener for catheter
US4776944 *1 Sep 198711 Oct 1988Jiri JanataChemical selective sensors utilizing admittance modulated membranes
US4777953 *25 Feb 198718 Oct 1988Ash Medical Systems, Inc.Capillary filtration and collection method for long-term monitoring of blood constituents
US4779618 *12 Aug 198525 Oct 1988Siemens AktiengesellschaftDevice and method for the physiological frequency control of a heart pacemaker equipped with a stimulating electrode
US4781798 *8 May 19871 Nov 1988The Regents Of The University Of CaliforniaTransparent multi-oxygen sensor array and method of using same
US4784736 *7 Jul 198615 Nov 1988Bend Research, Inc.Functional, photochemically active, and chemically asymmetric membranes by interfacial polymerization of derivatized multifunctional prepolymers
US4787837 *7 Aug 198629 Nov 1988Union Carbide CorporationWear-resistant ceramic, cermet or metallic embossing surfaces, methods for producing same, methods of embossing articles by same and novel embossed articles
US4795707 *25 Nov 19853 Jan 1989Hitachi, Ltd.Electrochemical sensor having three layer membrane containing immobilized enzymes
US4796634 *9 Aug 198510 Jan 1989Lawrence Medical Systems, Inc.Methods and apparatus for monitoring cardiac output
US4805624 *14 Apr 198721 Feb 1989The Montefiore Hospital Association Of Western PaLow-potential electrochemical redox sensors
US4805625 *8 Jul 198721 Feb 1989Ad-Tech Medical Instrument CorporationSphenoidal electrode and insertion method
US4871351 *26 Aug 19873 Oct 1989Vladimir FeingoldImplantable medication infusion system
US4871440 *6 Jul 19883 Oct 1989Daiken Industries, Ltd.Biosensor
US4874500 *15 Jul 198717 Oct 1989Sri InternationalMicroelectrochemical sensor and sensor array
US4890620 *17 Feb 19882 Jan 1990The Regents Of The University Of CaliforniaTwo-dimensional diffusion glucose substrate sensing electrode
US4894137 *14 Sep 198716 Jan 1990Omron Tateisi Electronics Co.Enzyme electrode
US4897162 *2 Feb 198830 Jan 1990The Cleveland Clinic FoundationPulse voltammetry
US4897173 *19 Jun 198630 Jan 1990Matsushita Electric Industrial Co., Ltd.Biosensor and method for making the same
US4898591 *9 Aug 19886 Feb 1990Mallinckrodt, Inc.Nylon-PEBA copolymer catheter
US4969468 *24 Jan 198913 Nov 1990Alfred E. Mann Foundation For Scientific ResearchElectrode array for use in connection with a living body and method of manufacture
US4970145 *20 Jan 198813 Nov 1990Cambridge Life Sciences PlcImmobilized enzyme electrodes
US4986271 *19 Jul 198922 Jan 1991The University Of New MexicoVivo refillable glucose sensor
US4994167 *7 Jul 198819 Feb 1991Markwell Medical Institute, Inc.Biological fluid measuring device
US4995402 *12 Oct 198826 Feb 1991Thorne, Smith, Astill Technologies, Inc.Medical droplet whole blood and like monitoring
US5055171 *22 Jun 19908 Oct 1991T And G CorporationIonic semiconductor materials and applications thereof
US5058592 *2 Nov 199022 Oct 1991Whisler G DouglasAdjustable mountable doppler ultrasound transducer device
US5082550 *11 Dec 198921 Jan 1992The United States Of America As Represented By The Department Of EnergyEnzyme electrochemical sensor electrode and method of making it
US5082786 *28 Nov 198821 Jan 1992Nec CorporationGlucose sensor with gel-immobilized glucose oxidase and gluconolactonase
US5089112 *11 Jan 199018 Feb 1992Associated Universities, Inc.Electrochemical biosensor based on immobilized enzymes and redox polymers
US5161532 *19 Apr 199010 Nov 1992Teknekron Sensor Development CorporationIntegral interstitial fluid sensor
US5165407 *9 Apr 199124 Nov 1992The University Of KansasImplantable glucose sensor
US5184619 *2 Oct 19879 Feb 1993Peritronics Medical, Inc.Intrauterine pressure and fetal heart rate sensor
US5250439 *14 Dec 19925 Oct 1993Miles Inc.Use of conductive sensors in diagnostic assays
US5262035 *2 Aug 198916 Nov 1993E. Heller And CompanyEnzyme electrodes
US5262305 *3 Sep 199116 Nov 1993E. Heller & CompanyInterferant eliminating biosensors
US5264092 *2 Oct 199123 Nov 1993Moltech CorporationRedox polymer modified electrode for the electrochemical regeneration of coenzyme
US5264103 *15 Oct 199223 Nov 1993Matsushita Electric Industrial Co., Ltd.Biosensor and a method for measuring a concentration of a substrate in a sample
US5264104 *8 May 199223 Nov 1993Gregg Brian AEnzyme electrodes
US5264105 *17 Mar 199323 Nov 1993Gregg Brian AEnzyme electrodes
US5264106 *18 Mar 199323 Nov 1993Medisense, Inc.Enhanced amperometric sensor
US5279294 *26 Mar 199018 Jan 1994Cascade Medical, Inc.Medical diagnostic system
US5285792 *10 Jan 199215 Feb 1994Physio-Control CorporationSystem for producing prioritized alarm messages in a medical instrument
US5286362 *27 Apr 199315 Feb 1994Boehringer Mannheim GmbhMethod and sensor electrode system for the electrochemical determination of an analyte or an oxidoreductase as well as the use of suitable compounds therefor
US5286364 *29 Mar 199115 Feb 1994Rutgers UniversitySurface-modified electochemical biosensor
US5288636 *14 Dec 199022 Feb 1994Boehringer Mannheim CorporationEnzyme electrode system
US5352348 *3 Nov 19924 Oct 1994Nova Biomedical CorporationMethod of using enzyme electrode
US5356786 *2 Dec 199318 Oct 1994E. Heller & CompanyInterferant eliminating biosensor
US5368028 *16 Jun 199329 Nov 1994Cb-Carmel Biotechnology Ltd.System for monitoring and controlling blood and tissue constituent levels
US5378628 *19 Feb 19923 Jan 1995Asulab, S.A.Sensor for measuring the amount of a component in solution
US5387327 *19 Oct 19927 Feb 1995Duquesne University Of The Holy GhostImplantable non-enzymatic electrochemical glucose sensor
US5390671 *15 Mar 199421 Feb 1995Minimed Inc.Transcutaneous sensor insertion set
US5391250 *15 Mar 199421 Feb 1995Minimed Inc.Method of fabricating thin film sensors
US5462051 *31 Aug 199431 Oct 1995Colin CorporationMedical communication system
US5462645 *21 Sep 199231 Oct 1995Imperial College Of Science, Technology & MedicineDialysis electrode device
US5469846 *27 Sep 199428 Nov 1995Duquesne University Of The Holy GhostImplantable non-enzymatic electrochemical glucose sensor
US5494562 *27 Jun 199427 Feb 1996Ciba Corning Diagnostics Corp.Electrochemical sensors
US5560357 *27 Jan 19951 Oct 1996Biofield Corp.D.C. epidermal biopotential sensing electrode assembly and apparatus for use therewith
US5565085 *25 Apr 199515 Oct 1996Matsushita Electric Industrial Co., Ltd.Method for quantifying specific compound
US5567302 *7 Jun 199522 Oct 1996Molecular Devices CorporationElectrochemical system for rapid detection of biochemical agents that catalyze a redox potential change
US5568806 *16 Feb 199529 Oct 1996Minimed Inc.Transcutaneous sensor insertion set
US5569186 *25 Apr 199429 Oct 1996Minimed Inc.Closed loop infusion pump system with removable glucose sensor
US5593852 *1 Sep 199414 Jan 1997Heller; AdamSubcutaneous glucose electrode
US5596150 *8 Mar 199521 Jan 1997The United States Of America As Represented By The Administrator Of The National Aeronautics And Space AdministrationCapacitance probe for fluid flow and volume measurements
US5680858 *10 Dec 199328 Oct 1997Novo Nordisk A/SMethod and apparatus for in vivo determination of the concentration in a body fluid of metabolically significant substances
US5682233 *20 Nov 199628 Oct 1997Integ, Inc.Interstitial fluid sampler
US5708247 *14 Feb 199613 Jan 1998Selfcare, Inc.Disposable glucose test strips, and methods and compositions for making same
US5711001 *29 May 199620 Jan 1998Motorola, Inc.Method and circuit for acquisition by a radio receiver
US5711861 *22 Nov 199527 Jan 1998Ward; W. KennethDevice for monitoring changes in analyte concentration
US5711862 *15 Mar 199627 Jan 1998Omron CorporationPortable biochemical measurement device using an enzyme sensor
US5820551 *6 Jun 199513 Oct 1998Hill; Hugh Allen OliverStrip electrode with screen printing
US5822715 *18 Apr 199713 Oct 1998Health Hero NetworkDiabetes management system and method for controlling blood glucose
US5827183 *29 Oct 199727 Oct 1998Cygnus, Inc.Method of measuring chemical concentration iontophoretically using impermeable mask
US5840020 *5 Feb 199724 Nov 1998Nokia Mobile Phones, Ltd.Monitoring method and a monitoring equipment
US5964993 *19 Dec 199612 Oct 1999Implanted Biosystems Inc.Glucose sensor
US5965380 *12 Jan 199912 Oct 1999E. Heller & CompanySubcutaneous glucose electrode
US5972199 *11 Feb 199726 Oct 1999E. Heller & CompanyElectrochemical analyte sensors using thermostable peroxidase
US5995860 *6 Jul 199530 Nov 1999Thomas Jefferson UniversityImplantable sensor and system for measurement and control of blood constituent levels
US6020110 *23 Jun 19951 Feb 2000Cambridge Sensors Ltd.Production of electrodes for electrochemical sensing
US6024699 *13 Mar 199815 Feb 2000Healthware CorporationSystems, methods and computer program products for monitoring, diagnosing and treating medical conditions of remotely located patients
US6134461 *4 Mar 199817 Oct 2000E. Heller & CompanyElectrochemical analyte
US6175752 *30 Apr 199816 Jan 2001Therasense, Inc.Analyte monitoring device and methods of use
US6484046 *10 Jul 200019 Nov 2002Therasense, Inc.Electrochemical analyte sensor
US6514718 *29 Nov 20014 Feb 2003Therasense, Inc.Subcutaneous glucose electrode
US6629776 *12 Dec 20017 Oct 2003Mini-Mitter Company, Inc.Digital sensor for miniature medical thermometer, and body temperature monitor
US6638772 *17 Jun 199728 Oct 2003Amire MedicalElectrochemical test device
US6689056 *6 Apr 200010 Feb 2004Medtronic Endonetics, Inc.Implantable monitoring probe
US6990366 *24 Nov 200324 Jan 2006Therasense, Inc.Analyte monitoring device and methods of use
US7003340 *11 Nov 200221 Feb 2006Abbott Diabetes Care Inc.Electrochemical analyte sensor
US7003341 *24 Nov 200321 Feb 2006Abbott Diabetes Care, Inc.Analyte monitoring devices and methods of use
US7134999 *22 Aug 200314 Nov 2006Dexcom, Inc.Optimized sensor geometry for an implantable glucose sensor
US7136689 *19 Jan 200514 Nov 2006Dexcom, Inc.Device and method for determining analyte levels
US7276029 *1 Aug 20032 Oct 2007Dexcom, Inc.System and methods for processing analyte sensor data
US7591801 *26 Feb 200422 Sep 2009Dexcom, Inc.Integrated delivery device for continuous glucose sensor
US7599726 *14 Apr 20086 Oct 2009Dexcom, Inc.System and methods for processing analyte sensor data
US7613491 *14 Apr 20063 Nov 2009Dexcom, Inc.Silicone based membranes for use in implantable glucose sensors
US7615007 *26 Mar 200710 Nov 2009Dexcom, Inc.Analyte sensor
US7651596 *18 Jan 200626 Jan 2010Dexcom, Inc.Cellulosic-based interference domain for an analyte sensor
US20030023317 *27 Jul 200130 Jan 2003Dexcom, Inc.Membrane for use with implantable devices
US20030032874 *27 Jul 200113 Feb 2003Dexcom, Inc.Sensor head for use with implantable devices
US20030217966 *22 May 200227 Nov 2003Dexcom, Inc.Techniques to improve polyurethane membranes for implantable glucose sensors
US20040011671 *27 Jul 200122 Jan 2004Dexcom, Inc.Device and method for determining analyte levels
US20040199059 *22 Aug 20037 Oct 2004Dexcom, Inc.Optimized sensor geometry for an implantable glucose sensor
US20050031689 *10 May 200410 Feb 2005Dexcom, Inc.Biointerface membranes incorporating bioactive agents
US20050043598 *22 Aug 200324 Feb 2005Dexcom, Inc.Systems and methods for replacing signal artifacts in a glucose sensor data stream
US20050245795 *3 May 20043 Nov 2005Dexcom, Inc.Implantable analyte sensor
US20050245799 *3 May 20043 Nov 2005Dexcom, Inc.Implantable analyte sensor
US20060003398 *15 Jul 20055 Jan 2006Therasense, Inc.Subcutaneous glucose electrode
US20060015020 *6 Jul 200419 Jan 2006Dexcom, Inc.Systems and methods for manufacture of an analyte-measuring device including a membrane system
US20060016700 *21 Jun 200526 Jan 2006Dexcom, Inc.Transcutaneous analyte sensor
US20060019327 *10 Mar 200526 Jan 2006Dexcom, Inc.Transcutaneous analyte sensor
US20060020186 *10 Mar 200526 Jan 2006Dexcom, Inc.Transcutaneous analyte sensor
US20060020188 *10 Mar 200526 Jan 2006Dexcom, Inc.Transcutaneous analyte sensor
US20060020189 *10 Mar 200526 Jan 2006Dexcom, Inc.Transcutaneous analyte sensor
US20060020190 *10 Mar 200526 Jan 2006Dexcom, Inc.Transcutaneous analyte sensor
US20060020191 *10 Mar 200526 Jan 2006Dexcom, Inc.Transcutaneous analyte sensor
US20060020192 *10 Mar 200526 Jan 2006Dexcom, Inc.Transcutaneous analyte sensor
US20060036139 *10 Mar 200516 Feb 2006Dexcom, Inc.Transcutaneous analyte sensor
US20060036140 *10 Mar 200516 Feb 2006Dexcom, Inc.Transcutaneous analyte sensor
US20060036141 *10 Mar 200516 Feb 2006Dexcom, Inc.Transcutaneous analyte sensor
US20060036142 *10 Mar 200516 Feb 2006Dexcom, Inc.Transcutaneous analyte sensor
US20060036143 *10 Mar 200516 Feb 2006Dexcom, Inc.Transcutaneous analyte sensor
US20060036144 *21 Jun 200516 Feb 2006Dexcom, Inc.Transcutaneous analyte sensor
US20060036145 *21 Jun 200516 Feb 2006Dexcom, Inc.Transcutaneous analyte sensor
US20060222566 *18 Jan 20065 Oct 2006Brauker James HTranscutaneous analyte sensor
US20070016381 *1 Sep 200618 Jan 2007Apurv KamathSystems and methods for processing analyte sensor data
US20070042377 *25 Oct 200422 Feb 2007Zhiqiang GaoBiosensor
US20070235331 *18 May 200711 Oct 2007Dexcom, Inc.Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
US20080021666 *1 Oct 200724 Jan 2008Dexcom, Inc.System and methods for processing analyte sensor data
US20080033254 *13 Jun 20077 Feb 2008Dexcom, Inc.Systems and methods for replacing signal data artifacts in a glucose sensor data stream
US20080045824 *14 Jun 200721 Feb 2008Dexcom, Inc.Silicone composition for biocompatible membrane
US20080242961 *11 Jun 20082 Oct 2008Dexcom, Inc.Transcutaneous analyte sensor
US20080262469 *5 Jun 200823 Oct 2008Dexcom. Inc.Integrated medicament delivery device for use with continuous analyte sensor
US20080275313 *17 Jul 20086 Nov 2008Dexcom, Inc.Transcutaneous analyte sensor
US20080287764 *29 Jul 200820 Nov 2008Dexcom, Inc.Integrated receiver for continuous analyte sensor
US20080287765 *29 Jul 200820 Nov 2008Dexcom, Inc.Integrated receiver for continuous analyte sensor
US20080287766 *29 Jul 200820 Nov 2008Dexcom, Inc.Integrated receiver for continuous analyte sensor
US20090012379 *20 Aug 20088 Jan 2009Dexcom, Inc.System and methods for processing analyte sensor data
US20090018424 *25 Mar 200815 Jan 2009Dexcom, Inc.Analyte sensor
US20090030294 *7 Oct 200829 Jan 2009Dexcom, Inc.Implantable analyte sensor
US20090036758 *16 Oct 20085 Feb 2009Dexcom, Inc.Signal processing for continuous analyte sensor
US20090036763 *14 Oct 20085 Feb 2009Dexcom, Inc.Analyte sensor
US20090043181 *16 Oct 200812 Feb 2009Dexcom, Inc.Signal processing for continuous analyte sensor
US20090043182 *16 Oct 200812 Feb 2009Dexcom, Inc.Signal processing for continuous analyte sensor
US20090043525 *16 Oct 200812 Feb 2009Dexcom, Inc.Signal processing for continuous analyte sensor
US20090043541 *16 Oct 200812 Feb 2009Dexcom, Inc.Signal processing for continuous analyte sensor
US20090242399 *25 Mar 20081 Oct 2009Dexcom, Inc.Analyte sensor
US20090242425 *25 Mar 20081 Oct 2009Dexcom, Inc.Analyte sensor
US20090247855 *27 Mar 20091 Oct 2009Dexcom, Inc.Polymer membranes for continuous analyte sensors
US20090247856 *27 Mar 20091 Oct 2009Dexcom, Inc.Polymer membranes for continuous analyte sensors
US20090287073 *29 Jul 200919 Nov 2009Dexcom, Inc.Silicone based membranes for use in implantable glucose sensors
US20090287074 *4 Aug 200919 Nov 2009Dexcom, Inc.Analyte sensor
US20100010324 *23 Sep 200914 Jan 2010Dexcom, Inc.Signal processing for continuous analyte sensor
US20100010331 *23 Sep 200914 Jan 2010Dexcom, Inc.Signal processing for continuous analyte sensor
US20100010332 *23 Sep 200914 Jan 2010Dexcom, Inc.Signal processing for continuous analyte sensor
US20100016687 *23 Sep 200921 Jan 2010Dexcom, Inc.Signal processing for continuous analyte sensor
US20100016698 *23 Sep 200921 Jan 2010Dexcom, Inc.Integrated receiver for continuous analyte sensor
US20100022855 *23 Sep 200928 Jan 2010Dexcom, Inc.Signal processing for continuous analyte sensor
USRE35648 *13 Jul 19954 Nov 1997Radi Medical Systems AbSensor guide construction and use thereof
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US838269630 Jun 201026 Feb 2013Fresenius Medical Care Holdings, Inc.Drug delivery devices and related systems and methods
US842548730 Jun 201023 Apr 2013Fresenius Medical Care Holdings, Inc.Drug vial spikes, fluid line sets, and related systems
US856258430 Jun 201022 Oct 2013Fresenius Medical Care Holdings, Inc.Drug delivery devices and related systems and methods
US913206126 Mar 201315 Sep 2015Fresenius Medical Care Holdings, Inc.Drug vial spikes, fluid line sets, and related systems
US913837930 Jun 201022 Sep 2015Fresenius Medical Care Holdings, Inc.Drug delivery methods and related products
US914464613 Mar 201329 Sep 2015Fresenius Medical Care Holdings, Inc.Vial spiking devices and related assemblies and methods
US928314526 Mar 201315 Mar 2016Fresenius Medical Care Holdings, Inc.Drug vial spikes, fluid line sets, and related systems
US20110004143 *30 Jun 20106 Jan 2011Michael James BeirigerDrug Delivery Devices And Related Systems And Methods
US20110004144 *30 Jun 20106 Jan 2011Michael James BeirigerDrug Delivery Devices And Related Systems And Methods
US20110004145 *30 Jun 20106 Jan 2011Michael James BeirigerDrug Vial Spikes, Fluid Line Sets, And Related Systems
US20110004187 *30 Jun 20106 Jan 2011Michael James BeirigerDrug Delivery Methods And Related Products
U.S. Classification600/347, 600/345
International ClassificationA61B5/145, A61B5/1486, G01N27/327, A61B5/1495, C12Q1/54, C12M1/40, A61B5/1473, C12Q1/00
Cooperative ClassificationY10S435/962, Y10S435/817, Y10S435/917, C12Q1/006, C12Q1/54
European ClassificationC12Q1/54, C12Q1/00B6B